Tag Archives: regn

Are 4 Top-Rated IBD 50 Drug Stocks On Your Radar?

The IBD 50 is a ranking of leading stocks based on key fundamental and technical measures including earnings and sales growth, profit margins, return on equity and relative price performance. Here’s a closer look at four drug stocks that made the new list Friday: Regeneron Pharmaceuticals (REGN), Valeant Pharmaceuticals (VRX), Actavis (ACT) and Gilead Sciences (GILD). Regeneron has a highest possible IBD Composite Rating of 99. On Friday, the FDA

Regeneron/Sanofi Cholesterol Drug Under FDA Scrutiny

Speculation about the newest class of cholesterol drugs heated up Friday after the FDA released briefing documents for Tuesday’s advisory committee meeting on Praluent, the PCSK9 inhibitor from Regeneron Pharmaceuticals (REGN) and Sanofi (SNY). Nevertheless, Regeneron stock rose to an all-time high Friday for the second straight day. The documents framed the issues to ponder when the panel votes on whether to recommend approving the drug, advice

Meet 8 Hot Med Stocks Among IBD’s Big Cap Leaders

IBD’s Big Cap Leaders screen filters through highly liquid, large-cap stocks with a strong record of earnings growth. Eight top-notch medical stocks that made the screen’s cut are Valeant Pharmaceuticals (VRX), Gilead Sciences (GILD), Celgene (CELG), Actavis (ACT), Biogen (BIIB), Regeneron (REGN), Shire (SHPG) and Illumina (ILMN). Valeant Pharmaceuticals has a highest-possible IBD Composite Rating of 99, meaning its shares outperform 99% of all